. 2008 Jul 31;19(6):420–428. doi: 10.1007/s00335-008-9125-x

Table 2.

List of all arthritis experiments of DA substrains

EXP-ID	Immunogen	DA substrains	Incidence of arthritis	Day of onset (mean ± SD)^a	Maximal arthritis score (mean ± SD)^a
EXP-01	50 μl pristane	DA/OlaHsd	25/26	12 ± 2	39 ± 11
EXP-01	50 μl pristane	DA/ZtmRhd	13/27*	14 ± 2*	25 ± 11*
EXP-02	50 μl pristane	DA/OlaHsd	26/29	12 ± 2	46 ± 9
EXP-02	50 μl pristane	DA/ZtmRhd	13/27*	12 ± 1	40 ± 8*
EXP-03^b	150 μl pristane	DA/ZtmRhd	9/10	13 ± 2	27 ± 14
EXP-04	75 μg CII/100 μl	DA/OlaHsd	20/20	15 ± 2	36 ± 18
EXP-04	75 μg CII/100 μl	DA/ZtmRhd	20/22	18 ± 3*	21 ± 15*
EXP-05	75 μg CII/100 μl	DA/OlaHsd	18/19	14 ± 1	53 ± 10
EXP-05	75 μg CII/100 μl	DA/ZtmRhd	17/17	16 ± 2*	33 ± 17*

SD = standard deviation

^aOnly affected animals included

^bExperiment was terminated at day 16

* Significantly different (p < 0.05) from DA/OlaHsd